ストックスクリーナーアプリを入手
28.24
0.49%
-0.14
アフターアワーズ：
28.24
Acadia Pharmaceuticals Inc (ACAD) 最新ニュース
48,794 Shares in ACADIA Pharmaceuticals Inc. $ACAD Purchased by State of Wyoming - MarketBeat
Assenagon Asset Management S.A. Sells 57,075 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Bank of America Corp DE Acquires 332,325 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $33.05, Implies 17% Upside - TradingView
STATE STREET CORP Adds to ACADIA Pharmaceuticals Inc (ACAD) Stak - GuruFocus
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
Canaccord reiterates Acadia Pharmaceuticals stock rating on products By Investing.com - Investing.com Canada
Canaccord reiterates Acadia Pharmaceuticals stock rating on products - Investing.com India
Royal Bank of Canada Trims Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia Pharmaceuticals at Canaccord Genuity conference: growth, pipeline - Investing.com India
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data - TradingView
Acadia Pharmaceuticals at Canaccord Genuity conference: growth, pipeline By Investing.com - Investing.com Nigeria
ACAD: DAYBUE STIX is quickly overtaking the original formulation as European launch preparations advance - TradingView
Acadia Pharmaceuticals stock hits 52-week high at $29.81 - Investing.com
Acadia Pharmaceuticals stock hits 52-week high at $29.81 By Investing.com - Investing.com Australia
ACADIA Pharmaceuticals (NASDAQ:ACAD) Gains Fresh Market Attention - Kalkine Media
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $41.00 Price Target at Needham & Company LLC - MarketBeat
ACAD Maintains Buy Rating by Needham -- Price Target Raised to $41 - GuruFocus
Needham Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $41 - Moomoo
ACADIA Pharmaceuticals (ACAD) On Raised 2026 Guidance And Strong Results Looks Undervalued - Sahm
Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript - AOL.com
ACADIA Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History - Yahoo! Finance Canada
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits Fresh High: What Now? - Kalkine Media
Morgan Stanley Adjusts PT on ACADIA Pharmaceuticals to $27 From $26, Maintains Equalweight Rating - Moomoo
Janus Henderson Group PLC Decreases Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 52-Week HighWhat's Next? - MarketBeat
Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says - Moomoo
Immunic appoints Elena Ridloff to board of directors - Yahoo Finance
ACAD Maintained by Citigroup -- Price Target Raised to $39.00 - GuruFocus
ACADIA Pharmaceuticals Inc. Revenue Breakdown – BIVA:ACAD - TradingView
Sei Investments Co. Lowers Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Empowered Funds LLC Purchases Shares of 48,982 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Acadia CFO Mark Schneyer sells $587k in company stock - Investing.com
Acadia CFO Mark Schneyer sells $587k in company stock By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded to Buy at Wall Street Zen - MarketBeat
Mark Schneyer Sells 5,849 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock - MarketBeat
Mark Schneyer Sells 14,292 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock - MarketBeat
Acadia Pharmaceuticals (ACAD) Stock Gets Fair Value Bump As Analysts Back Daybue Growth - Yahoo Finance
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year? - Yahoo Finance
State Street Corporation (ACAD) discloses 5.3% Acadia Pharma stake on 13G - Stock Titan
What is HC Wainwright's Estimate for ACAD FY2026 Earnings? - MarketBeat
Guggenheim Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
HC Wainwright Analysts Increase Earnings Estimates for ACAD - MarketBeat
H.C. Wainwright reiterates Acadia Pharmaceuticals stock rating By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals (ACAD) Stock Jumps As Valuation Gap Draws Focus - Sahm
3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations - TradingView
ACADIA PHARMACEUTICALS INC SEC Filing (Aug 5, 2026) - Stock Titan
ACADIA Pharmaceuticals (ACAD) Maintains Rating at Perform -- Pri - GuruFocus
ACADIA Pharmaceuticals Inc. Revenue Breakdown – BMV:ACAD - TradingView
ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $33.25, Implies 22% Upside - TradingView
BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $31 - Moomoo
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $36 to $38 - Moomoo
Morgan Stanley Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Maintains Target Price $26 - moomoo.com
ACAD Maintained by Citizens -- Price Target Raised to $36.00 - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, Citizens Jmp Analyst Says - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year High After Strong Earnings - marketbeat.com
Acadia Pharmaceuticals stock hits 52-week high at 28.4 USD - Investing.com
ACADIA Pharmaceuticals Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ACAD) 2026-08-05 - Seeking Alpha
Acadia Pharmaceuticals stock hits 52-week high at 28.4 USD By Investing.com - Investing.com UK
RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $36, Maintains Outperform Rating - marketscreener.com
Oppenheimer raises Acadia Pharmaceuticals price target on Daybue beat By Investing.com - Investing.com South Africa
ACADIA PHARMACEUTICALS INC Quarterly Earnings Report - stocktitan.net
ACADIA Pharmaceuticals Inc (ACAD) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Is Acadia Pharmaceuticals (ACAD) Fairly Valued After Q2 Earnings - GuruFocus
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):